Uric acid and HMGB1 are involved in the induction of autoantibodies elicited in mice infected with mouse hepatitis virus A59

Autoimmunity

Volumn 44, Issue 8, 2011, Pages 631-640

  Duhalde Vega, Maite ^a   Retegui, Lilia A ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Autoantibodies; Autoimmunity; HMGB1; Mouse hepatitis virus; Uric acid

Indexed keywords

ALLOPURINOL; AUTOANTIBODY; FUMARYLACETOACETASE ANTIBODY; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; FEMALE; HEPATITIS; IMMUNOREACTIVITY; MOUSE; MURINE HEPATITIS CORONAVIRUS; MURINE HEPATITIS CORONAVIRUS A59; NONHUMAN; PROTEIN BLOOD LEVEL; URIC ACID BLOOD LEVEL; VIRUS STRAIN;

ALLOPURINOL; ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; CORONAVIRUS INFECTIONS; FEMALE; HEPATITIS, VIRAL, ANIMAL; HMGB1 PROTEIN; HYDROLASES; LIVER; MICE; MICE, INBRED BALB C; MURINE HEPATITIS VIRUS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PYRUVATES; SIGNAL TRANSDUCTION; URIC ACID;

EID: 80053238198     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2011.579927     Document Type: Article

References (38)

1. Coutelier J.-P., Coulie PG, Wauters P, Heremans H, Van Der Logt JTM. In vivo polyclonal B-lymphocyte activation elicited by murine viruses. J Virol 1990;64:5383-5388. (Pubitemid 20364529)
2. Godfraind C, Coutelier J.-P. Morphological analysis of mouse hepatitis virus A59-induced pathology with regard to viral receptor expression. Histol Histopathol 1998;13: 181-199. (Pubitemid 28044611)
3. Mathieu PA, Gómez KA, Coutelier J.-P., Retegui LA. Identification of two liver proteins recognized by autoantibodies elicited in mice infected with mouse hepatitis virus A59. Eur J Immunol 1996;31:1447-1455. (Pubitemid 32454692)
4. Mathieu PA, Gómez KA, Coutelier J.-P., Retegui LA. Sequence similarity and structural homologies are involved in the autoimmune response elicited by mouse hepatitis virus A59. J Autoimmun 2004;23:117-126. (Pubitemid 39485793)
5. Duhalde-Vega M, Loureiro ME, Mathieu PA, Retegui LA. The peptide specificities of the autoantibodies elicited by mouse hepatitis virus A59. J Autoimmun 2006;27:203-209. (Pubitemid 46048596)
6. Duhalde-Vega M, Aparicio JL, Retegui LA. Fine specificity of autoantibodies induced by mouse hepatitis virus A59. Viral Immunol 2009;22:287-294.
7. Routsias JG, Tzioufas AG, Moutsopoulos HM. The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases. Clin Chim Acta 2004;340:1-25. (Pubitemid 38167505)
8. Matzinger P. The danger model: A renewed sense of self. Science 2002;296:301-305. (Pubitemid 34303674)
9. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008;8:279-289. (Pubitemid 351432799)
10. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003;425:516-521. (Pubitemid 37237047)
11. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: Endogenous danger signaling. Mol Med 2008;14: 476-484.
12. Pisetsky DS, Erlandsson-Harris H, Andersson U. Highmobility group box protein 1 (HMGB1): An alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 2008;10:1-10.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with the folin phenol reagent. J Biol Chem 1951;193:265-275.
14. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72: 248-254.
15. Hu DH, Moore AM, Thomsen LL, Brindle MK. Uric acid promotes tumor immune rejection. Cancer Res 2004;64: 5059-5062. (Pubitemid 39006518)
16. Tasci I, Deveci S, Isik AT, Comert B, Akay C, Mas N, Inal V, Yamanel L, Mas MR. Allopurinol in rat chronic pancreatitis: Effects on pancreatic stellate cell activation. Pancreas 2007;35: 366-371. (Pubitemid 350307382)
17. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, Czura CJ, Fink MP, Tracey KJ. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002;99: 12351-12356.
18. Uchiyama T, Delude RL, Fink MP. Dose-dependent effect of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intensive Care Med 2003;29:2050-2058 (Pubitemid 37492897)
19. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-983. (Pubitemid 32885676)
20. Kato C, Sato K, Wakabayashi A, Eishi Y. The effects of allopurinol on immune function in normal BALB/c and SCID mice. Int Immunopharmacol 2000;7:547-556. (Pubitemid 30214127)
21. Yang Z-Y, Ling Y, Yin T, Tao J, Xion J-X,Wu H-S,Wang C-Y. Delayed ethyl pyruvate therapy attenuates experimental severe acute pancreatitis via reduced serum high mobility group box 1 in rats.World J Gastroenterol 2008;14:4546-4550.
22. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004;4: 372-377. (Pubitemid 38987064)
23. Fink MP. Ethyl pyruvate: A novel anti-inflammatory agent. J Intern Med 2007;261:349-362. (Pubitemid 46474763)
24. Hang Y, Englert JA, Yang R, Delude RL, Fink MP. Ethyl piruvate inhibits nuclear factor-kB-dependent by directly targeted p65. J Pharmacol Exp Ther 2005;312:1097-1105. (Pubitemid 40293769)
25. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009;9: 353-362.
26. Plotz PH. The autoantibody repertoire: Searching for order. Nat Rev Immunol 2003;3:73-78. (Pubitemid 37328701)
27. Aparicio JL, Duhalde-Vega M, Loureiro ME, Retegui LA. The autoimmune response induced by mouse hepatitis virus A59 is expanded by a hepatotoxic agent. Int Immunopharmacol 2009;9:627-631.
28. Ma X, Jia YT, Qiu DK. Inhibition of p38 mitogen-activated protein kinase attenuates experimental autoimmune hepatitis: Involvement of nuclear factor kappa B. World J Gastroenterol 2007;13:4249-4254. (Pubitemid 47377165)
29. Lim SC, Choi JE, Kim CH, Duong HQ, Jeong GA, Kang HS, Han SI. Ethyl pyruvate induces necrosis-to-apoptosis switch and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. Int J Mol Med 2007;20:187-218.
30. Fink MP. Ethyl pyruvate. Curr Opin Anaesthesiol 2008;2: 160-167.
31. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008;11:4026-4030.
32. Campana L, Bosurgi L, Rovere-Querini P. HMGB1: A twoheaded signal regulating tumor progression and immunity. Curr Opin Immunol 2008;20:1-6.
33. Pétrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: A danger sensing complex triggering innate immunity. Curr Opin Immunol 2007;19:615-622. (Pubitemid 350236810)
34. Schroeder K, Zhou R, Tschopp J. The NLRP3 inflammasome: A sensor for metabolic danger? Science 2010;327: 296-300.
35. Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008;180:2531-2537.
36. Grus FH, Augustin AJ, Loeffler K, Lutz J, Pfeiffer N. Immunological effects of allopurinol in the treatment of experimental autoimmune uveitis (EAU) after onset of the disease. Eur J Ophthalmol 2003;13:185-191. (Pubitemid 36433863)
37. Namazi MR. Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. Int Immunopharmacol 2004;4:349-353. (Pubitemid 38375968)
38. Kutzing MK, Firestein BL. Altered uric acid levels and disease states. J Pharmacol Exp Ther 2008;324:1-7. (Pubitemid 350294141)